Approaches to the management of relapsed/refractory mantle cell lymphoma: navigating an increasingly complex therapeutic landscape

Genomic Determinants of Response and Resistance to Pirtobrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia

Recent advances and future directions in newly diagnosed mantle cell lymphoma

Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study

Non-Covalent BTK Inhibitors—The New BTKids on the Block for B-Cell Malignancies

Professor Cheah Discusses Early Results for LOXO-305 Trial